Creative Biolabs Boosts the Novel Therapeutics Through First-class Antibody Products

 Breaking News
  • No posts were found

Creative Biolabs Boosts the Novel Therapeutics Through First-class Antibody Products

May 01
13:48 2020

Creative Biolabs, as a reliable partner of recombinant antibody (rAb) discovery and manufacturing, provides standard molecular substances for research use to global customers who are working on discovering novel therapeutics to improve precision medicine.

Despite the fact that the whole America is affected by the pandemic COVID-19, scientists at Creative Biolabs could not relax for a moment, sticking to their post, and working devotedly to helping international customers in the pharmaceutical industry and research institutes. There are comprehensive products served which are in full stock, intended to reach the buyers at the fastest pace. Among them, engineered antibodies, MHC tetramer and detection kits for SARS-CoV-2 are on the best-seller list.

Some monoclonal antibodies, taken as the most promising tool for novel therapeutics because of their ability to attack disease-causing pathogens specifically, causing hardly any immunogenicity effects, have been approved by FDA for clinical use, with hundreds in clinical stages. To help customers excavate the mAb therapy with infinite market potential as much as possible, Creative Biolabs distributes comprehensive therapeutic antibodies, such as rodent antibodies, CDC/ADCC enhanced antibodies, human/humanized antibodies for research use, targeting common but crucial genes, and applicable to most of the labs’ conditions.

Taking advantage of the high-end in silico technology platforms and the scientists’ enriched experience, Creative Biolabs screened out qualified MHC tetramer assays to assist with characterizing and quantifying the specificity and phenotype of T cell immune response, covering the fields like cancer, virology, bacteriology, etc., to offer deeper and more thorough insights into the status of T cells produced during disease caused by cancer cells, viruses, bacteria, and so forth. Equally, they are intended for research use only and supported by considerate after-sale services.

Facing the COVID-19, Creative Biolabs has successfully developed SARS, MERS and other anti-viral antibody products for scientific study use owing to the large fund and energy invested in antibody development, with the aim to assist researchers with an in-depth understanding of SARS-CoV-2’s characteristics and accelerate the process of specific drug development. Recently, Creative Biolabs unveils novel research antibodies to support the research of COVID-19. For more details, please visit the official website to learn more.

About Creative Biolabs

Creative Biolabs is a leading figure in the field of antibody discovery and engineering with over 10 years of glorious history. Since establishment in 2004, experience and regular customers are accumulated, both of which prove the actual strength of this CRO company. Cutting-edge hybridoma development and phage display platforms developed by the scientists at Creative Biolabs can help produce recombinant antibody products at the most competitive price in the biotechnology industry, ranging from antibody/peptide libraries, biosimilar cell lines, chimeric antigen receptor (CAR) products, antibody-drug conjugates (ADCs) to engineered antibodies such as therapeutic antibodies, single-domain antibodies, bispecific antibodies and intrabodies.

Media Contact
Company Name: Creative Biolabs
Contact Person: Candy Swift
Email: Send Email
Phone: 1-631-619-7922
Country: United States

Related Articles